News Releases

Date Title and Summary View
Aug 27, 2018
Johnson & Johnson to Host Investor Conference Call on the Phase 3 MARINER and COMMANDER HF Studies for XARELTO®
Johnson & Johnson to Host Investor Conference Call on the Phase 3 MARINER and COMMANDER HF Studies for XARELTO® NEW BRUNSWICK, N.J., Aug. 27, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Monday, August 27th, to review
Aug 27, 2018
Aug 27, 2018
Aug 20, 2018
Johnson & Johnson to Host Investor Conference Call on the Pharmaceutical Business
NEW BRUNSWICK, N.J. , Aug. 20, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 10:00 a.m. (Eastern Time) on Thursday, September 13th, to review its Pharmaceutical Business.   Joaquin Duato, Vice Chairman of the Executive Committee; Jennifer Taubert,
Aug 08, 2018
Aug 07, 2018
Johnson & Johnson to Participate in the 2018 Wells Fargo 13th Annual Healthcare Conference
  NEW BRUNSWICK, N.J. , Aug. 7, 2018 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Wells Fargo 13 th Annual Healthcare Conference on Thursday, Sept. 6 th , at The Westin Copley Place  in Boston, MA.  Alex Gorsky, Chairman and Chief Executive Officer will represent the
Aug 07, 2018
Johnson & Johnson to Participate in Barclays Global Consumer Staples Conference
NEW BRUNSWICK, N.J. , Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Conference on Thursday, Sept. 6 th , at the InterContinental, Boston , MA.  Jorge Mesquita , Executive Vice President, Worldwide Chairman, Consumer will
Jul 30, 2018
Johnson & Johnson Consumer Inc. Announces Agreement to Acquire Zarbee's, Inc., a Leader in Naturally-Based Healthcare Products
SKILLMAN, N.J. , July 30, 2018 /PRNewswire/ -- Johnson & Johnson Consumer Inc. announced today that it has entered into a definitive agreement to acquire Zarbee's, Inc., a privately held company that is a leader in naturally-based healthcare products.  The acquisition will include the full line of
Jul 17, 2018
Johnson & Johnson Reports 2018 Second-Quarter Results:
2018 Second-Quarter Sales of $20.8 Billion Increased 10.6% versus 2017
2018 Second-Quarter EPS was $1.45
2018 Adjusted Second-Quarter EPS of $2.10 increased 14.8%*
Accelerating Operational Sales Growth in the Second Quarter
Jul 16, 2018
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2018
NEW BRUNSWICK, N.J. , July 16, 2018 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2018 of $0.90 per share on the company's common stock.  The dividend is payable on September 11, 2018 to shareholders
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.